Download Files:
Products Details
Product Description
– Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing’s sarcoma, Wilms’ tumor[1][2][4][5].
Web ID
– HY-13062A
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C27H29NO10
Citations
– ACS Infect Dis. 2022 Jul 19.|Cancer Biol Ther. 2020 Apr 2;21(4):320-331.|Cancers (Basel). 2022 Oct 19;14(20):5127.|Cell Oncol. 2022 Aug 29.|Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. |Front Oncol. 2021 Apr 22;11:665763.|Front Oncol. 2021 Apr 6.|Leukemia. 2023 Mar 28.|Microb Drug Resist. 2020 Jan;26(1):81-88.|Oncol Lett. 2020 Jan;19(1):368-378.|Universidad De Salamanca. 2023|bioRxiv. 2023 Jan 13.|Cancers (Basel). 2021, 13(5), 1127.|Cell Mol Immunol. 2023 Jan;20(1):51-64.|Curr Pharm Anal. 2018 Jan, 14(1):53-59(7).|Front Genet. 05 August 2021.|J Control Release. 2022 Apr 22;346:136-147.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Transl Med. 2022 Jul 6;20(1):304.|Mol Cell Biochem. 2021 Feb;476(2):1233-1243.|Pharmaceutics. 2021, 13(5), 661.
References
– [1]Svensson SP, et al. Melanin inhibits cytotoxic effects of Doxorubicin and Daunorubicin in MOLT 4 cells. Pigment Cell Res. 2003 Aug;16(4):351-4|[2]Arozal W, et al. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions. Toxicology. 2011 Jan 11;279(1-3):91-9.|[3]Lehmann M, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7.|[4]Gervasoni JE Jr, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and Daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26|[5]Dano K, et al. Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res. 1972 Jun;32(6):1307-14.|[6]Emeline Bollaert, et al. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. Int J Mol Sci. 2021 May 13;22(10):5153. |[7]Cheng Wu, et al. Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. Eur J Pharm Sci. 2021 Dec 1;167:106013.
CAS Number
– 20830-81-3
Molecular Weight
– 527.52
SMILES
– O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O
Clinical Information
– Launched
Research Area
– Cancer; Infection; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– ADC Cytotoxin;Antibiotic;Apoptosis;Autophagy;Bacterial;DNA/RNA Synthesis;Topoisomerase
Isoform
– Daunorubicins/Doxorubicins;Topo II
Pathway
– Antibody-drug Conjugate/ADC Related;Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage
Product type
– Natural Products
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
